コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 teasome inhibitor MG132 and a Cullin5 (Cul5) dominant negative mutant.
2 d 293 cells stably expressing the PERK-K618A dominant negative mutant.
3 allele expressed, although not as a classic dominant-negative mutant.
4 steoclastogenesis was also inhibited by Dvl2 dominant negative mutants.
5 small) G-proteins yield nucleotide-depleted, dominant-negative mutants.
6 , and JNK were assessed using inhibitors and dominant-negative mutants.
7 n lesions, and we also examine phenotypes of dominant-negative mutants.
8 LN3 function by expression of a channel-dead dominant negative mutant (458DD/KK) or by knockdown of e
10 f that PI3K by either chemical inhibitors or dominant-negative mutants abrogated the inhibitory effec
11 ase and Akt by either chemical inhibitors or dominant-negative mutants abrogated the RNS60-mediated u
12 a-arrestin using either siRNA knockdown or a dominant negative mutant abrogates the enhanced CXCL12-d
13 and Cdc42 using pharmacologic inhibitors and dominant negative mutants also inhibited the fMLF-induce
14 1b and ZmETR2b that is present in the etr1-1 dominant negative mutant and expressed each protein in A
16 -Cys (DHHC) zinc finger protein; (ii) a GODZ dominant-negative mutant and an inhibitor of palmitoylat
19 ereas AP-1 activation decreased in both MSK1 dominant-negative mutants and in MSK1 knockdown cells.
20 ection of IL-6 promoter reporter constructs, dominant negative mutants, and electromobility shift ass
24 ockade of Egr-1 via forced expression of its dominant-negative mutant attenuated 15(S)-HETE-induced H
25 on via adenovirus-mediated expression of its dominant-negative mutant attenuated 15(S)-HETE-induced H
26 EB activation by pharmacologic inhibition or dominant negative mutants blocks the 5-LO-dependent elev
27 p1 activation by pharmacologic inhibition or dominant-negative mutant blocks the 12/15-LO-dependent e
28 holinos or a naturally occurring human BMP15 dominant-negative mutant (BMP15-Y235C) leads to embryos
30 red in the basilar artery of mice expressing dominant-negative mutants, but not in mice expressing wi
31 erestingly, overexpression of the Ubc9 trans-dominant-negative mutant C93A, which is a defective E2-S
32 yonic fibroblasts (MEFs) and overexpressed a dominant-negative mutant CKIepsilon (DN-CKIepsilon) in t
34 Knockdown of Arkadia or overexpression of a dominant-negative mutant completely abolishes transcript
35 Jam-B and Jam-C using antibodies, siRNA, or dominant-negative mutants completely interferes with lum
36 ng beta-catenin signaling by transfection of dominant-negative mutant constructs to either T-cell fac
37 -type CREB promoted SnoN expression, whereas dominant negative mutant CREB abrogated SnoN induction b
38 ression of GDP-locked Rab4S22N and Rab11S25N dominant-negative mutants decreased the steady-state Kv1
43 ochondrial fission through expression of the dominant-negative mutant DLP1-K38A eliminated this dynam
44 t, MSK1 COOH terminal or NH(2) terminal dead dominant negative mutants dramatically suppressed cell t
45 of TSHR internalization, and expression of a dominant-negative mutant dynamin, which inhibited intern
46 elta-small interfering RNA, or with PKCdelta dominant-negative mutant effectively increased a number
49 riggered by canonical Wnt ligands, LRP6, and dominant negative mutants for Axin and GSK3, indicating
51 n muscle-specific transgenic mice expressing dominant-negative mutant form of AMPK or in AdipoR1-knoc
52 not its mutant, or ectopic expression of the dominant-negative mutant form of ATF-6 protected cells f
53 teins mitofusin 1 or 2 or with Drp1(K38A), a dominant-negative mutant form of Drp1, increased the per
55 /2, and mitochondrial complex II; as well as dominant negative mutant forms of IkappaBalpha and NOX4
56 the role of Sar1p in pexophagy by expressing dominant-negative mutant forms of Sar1p in Pichia pastor
59 R2 using an inhibitor, short hairpin RNA and dominant-negative mutant HER2 abolished IR-induced activ
62 SOCS-3 in renal epithelial cells expressing dominant-negative mutant HNF-1beta rescues the defect in
66 ith endothelium-targeted overexpression of a dominant-negative mutant human insulin receptor (ESMIRO)
67 ng B16/OVA cells engineered to overexpress a dominant negative mutant IFN-gamma receptor (B16/OVA/DNM
68 e to IFN-gamma" (MIIG) mice, which express a dominant negative mutant IFN-gamma receptor in CD68+ cel
69 ce showed that the CDK2-DN protein acts as a dominant negative mutant in mature T cells as expected,
70 d how CHIP recognizes Hsp/c70, we utilized a dominant negative mutant in which loss of a conserved pr
71 terfering with BVES function by expressing a dominant-negative mutant in human corneal epithelial cel
72 on via gene silencing or overexpression of a dominant negative mutant increased human keratinocyte ce
74 ting recruitment of Vinculin by expressing a dominant-negative mutant increases the rate of furrow in
76 knockdown of alphaSNAP or expression of its dominant negative mutant induced epithelial cell apoptos
77 n of PKMzeta in mPFC by expressing a PKMzeta dominant-negative mutant induced depressive-like behavio
78 own, knock-out, and enforced expression of a dominant-negative mutant inhibited rictor ubiquitination
79 ase-defective DHX33 mutant (K94R) acted as a dominant negative mutant, inhibiting endogenous rRNA syn
80 aB-specific inhibitor or overexpression of a dominant negative mutant inhibitory NF-kappaB (IkappaBal
82 was severely impaired in cells expressing a dominant-negative mutant IRF3 and completely abrogated i
83 induced by Sgo1 depletion or expression of a dominant negative mutant is suppressed by ectopic expres
85 g a missense R174Q mutation, which acts as a dominant-negative mutant, is associated with thrombocyto
86 ediated engulfment, we used a combination of dominant-negative mutants, knockdown of specific signali
87 , we overexpressed beta-arrestin2-(1-320), a dominant negative mutant known to block receptor endocyt
88 lize with GPER, and expression of arrestin-2 dominant-negative mutants lacking clathrin- or beta-adap
89 -positive (LdRab5a:Q93L and LdRab5b:Q80L) or dominant-negative mutants (LdRab5a:N146I and LdRab5b:N13
90 small interfering RNA or by expression of a dominant negative mutant led to inhibition of wound-indu
92 NFAT-dependent manner and pharmacological or dominant negative mutant-mediated blockade of PKN1 funct
96 heavy chain depletion or expression of AP180 dominant-negative mutant not only disrupted clathrin-reg
98 Kalpha1 subunit, whereas the expression of a dominant negative mutant of AMPKalpha1 or ablation of AM
100 harmacological inhibitor and expression of a dominant negative mutant of c-Abl, we show an essential
102 CRAG knockdown by siRNA or expression of a dominant negative mutant of CRAG significantly attenuate
103 f HeLa cells with MLN4924 or expression of a dominant negative mutant of cullin1 inhibited the Vpu-me
104 ace OAT1 increases in cells transfected with dominant negative mutant of dynamin-2, a maneuver blocki
106 r pathways due to transgenic expression of a dominant negative mutant of Fas-associated death domain
108 rotein expression, while the expression of a dominant negative mutant of GATA-3 or a GATA-3 shRNA con
110 unoprecipitated with wild-type Hsc70, with a dominant negative mutant of Hsc70, and with the minimal
111 ith cardiomyocyte-restricted expression of a dominant negative mutant of IkappaBalpha (IkappaBalpha(S
112 o induce NRF2 because either expression of a dominant negative mutant of IkappaBalpha that leads to N
114 ylation of p38, and that overexpression of a dominant negative mutant of MKP-1 does the opposite.
116 and functional role of omega, we isolated a dominant negative mutant of omega (omega6), which is pre
120 lly, EEA1 down-regulation or expression of a dominant negative mutant of PKC-alpha blunts Ang II-indu
122 f rLCMV-LASVGP was only mildly affected by a dominant negative mutant of Rab5 and was independent of
124 ated gene transfer, that overexpression of a dominant negative mutant of Rac1 or local knockout of Ra
127 mic reticulum-derived vesicle formation by a dominant negative mutant of small GTPase Sar1 had no det
130 n of cyt b(558), which could be blocked by a dominant negative mutant of the clathrin-coated pit-asso
131 iving adenovirus that encoded KCNH2-G628S, a dominant negative mutant of the I(Kr) potassium channel
134 ited by the proteasome inhibitor MG132 and a dominant negative mutant of ubiquitin, K6W-Ub, indicatin
136 ag-ESCRT-I or -II fusions was inhibited by a dominant negative mutant of Vps4 ATPase similar to wild
137 same way as did reduced ARAP2 expression and dominant negative mutants of Arf6 and Rac1 reversed the
139 n of K(+) from the cells, or transfection of dominant negative mutants of dynamin-2 or Eps15 into the
140 R2, and ERS2, are present in Arabidopsis and dominant negative mutants of each that confer ethylene i
141 , while inhibiting Cdc42 signaling by either dominant negative mutants of FGD1 or Cdc42 suppressed os
142 is stimulated by FLASH and inhibited by both dominant negative mutants of FLASH and anti-FLASH antibo
145 However, Dynasore (dynamin inhibitor), the dominant negative mutants of NM23-H1 (dynamin activator)
146 on and was reduced in cells transfected with dominant negative mutants of p115-Rho GEF or RhoA, and b
147 ologs in a yeast model host or expression of dominant negative mutants of plant Rab5 greatly decrease
149 hanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek
152 terfering RNA, an AKT inhibitor as well as a dominant-negative mutant of AKT1, blocks this activation
154 tablished stable cell lines by introducing a dominant-negative mutant of AMPK alpha1 subunit or its s
156 ological inhibition of AMPK, expression of a dominant-negative mutant of AMPKalpha1, and P2Y receptor
158 2 target gene expression via expression of a dominant-negative mutant of ATF2 or expression of an ATF
160 e is shortened by betaTrCP but extended by a dominant-negative mutant of betaTrCP, by RSK1/S6K1 inhib
161 B) activation] or overexpression of TAM67 (a dominant-negative mutant of c-Jun) dramatically inhibite
162 e also found in transgenic mice expressing a dominant-negative mutant of Cadm4 lacking its cytoplasmi
165 p junction coupling by viral expression of a dominant-negative mutant of Cx26 (also known as Gjb2) or
167 iral-mediated gene transfer to overexpress a dominant-negative mutant of DVL in NAc, or by using a ph
168 pressor of IkappaBalpha, or FAK, and using a dominant-negative mutant of FAK (FRNK), blocks melanoma
170 h decreased cell viability in MDM, whereas a dominant-negative mutant of FOXO3a or small interfering
171 GSK3beta in the NAc, while overexpressing a dominant-negative mutant of GSK3beta promoted resilience
172 c mice with cardiac-specific expression of a dominant-negative mutant of IkappaB alpha (IkappaB alpha
175 to express either a constitutively active or dominant-negative mutant of Inhibitor of kappa B kinase
176 g, which could be rescued by expression of a dominant-negative mutant of Lef1 that interferes with be
180 ly, NRF2 overexpression inhibited, whereas a dominant-negative mutant of NRF2 exacerbated RAC1-depend
182 activation of NF-kappaB by Deltap21(ras), a dominant-negative mutant of p21(ras), supported the invo
183 specific expression of Pim-1 (Pim-WT) or the dominant-negative mutant of Pim-1 (Pim-DN) in transgenic
185 eplication-deficient adenovirus expressing a dominant-negative mutant of protein kinase B (Akt) compa
186 urther confirmed by the forced expression of dominant-negative mutant of protein kinase C delta.
189 and NF-kappaB, as well as transfection of a dominant-negative mutant of Ras (RasN17), significantly
190 differentiation by targeting expression of a dominant-negative mutant of retinoic acid receptor alpha
192 se observations suggest that D477G acts as a dominant-negative mutant of RPE65 that delays chromophor
193 r N',N'-dimethylsphingosine or expression of dominant-negative mutant of SK1(G82D) or specific small
195 addition, adenovirus-mediated expression of dominant-negative mutant of Src blocked 15(S)-HETE's eff
196 nt for the transformation process, because a dominant-negative mutant of Stat3 interferes with PI3K-i
197 n the transcriptional level, expression of a dominant-negative mutant of the basic region leucine zip
198 hageal adenocarcinoma cells of beta2SP and a dominant-negative mutant of the Notch coactivator master
199 f30-depleted cells or cells overexpressing a dominant-negative mutant of the protein results from abe
200 th cone morphology, expression of a putative dominant-negative mutant of the receptor, CS-HmLAR2, lea
202 Consistent with this effect, expressing a dominant-negative mutant of ULK1 or ATG4b or a ULK1-targ
203 the erythroid cell-specific expression of a dominant-negative mutant of USF, A-USF, in transgenic mi
210 rmed by the expression of well-characterized dominant-negative mutants of genes in this pathway and b
212 atory effect was inhibited, however, by both dominant-negative mutants of Mek2 (Mek2-K101A) and K-Ras
217 elial function in transgenic mice expressing dominant-negative mutants of PPARgamma under the control
220 generally cause pro-[PSI(+)] effects, since dominant-negative mutants of Ssa1 or Ssa2 cure [PSI(+)],
221 ology and Golgi movement through analyses of dominant-negative mutants of the putative GTPase domain
223 on of TNF-induced superoxide generation with dominant-negative mutants of TRADD or Rac1, as well as k
224 ignificance of signaling was confirmed using dominant negative mutants or pharmacological inhibitors.
227 eorganization of VIFs caused by expressing a dominant-negative mutant or by silencing vimentin with s
228 When vimentin organization is disrupted by a dominant-negative mutant or by silencing, there is a los
229 kyrin G function either by over-expressing a dominant-negative mutant or by siRNA knockdown decreases
231 hibiting endogenous chaperone molecules by a dominant-negative mutant or chemical inhibitors recapitu
232 Inactivation of HIF by expression of a HIF dominant-negative mutant or deletion of HIF-1alpha by RN
233 ion of Merlin transport by expression of the dominant-negative mutant or depletion of kinesin-1 resul
235 cells, we show that FOXO1 inhibition using a dominant-negative mutant or lentivirus-encoded small hai
236 ical conditions in vivo, blocking it using a dominant-negative mutant or lithium chloride prevented m
238 interaction of UL20 with GODZ, using a GODZ dominant-negative mutant or possibly GODZ shRNA, should
239 cilia and inhibition of Rab11 function by a dominant-negative mutant or RNA interference blocks prim
240 ession of endogenous beta-TrCP function by a dominant-negative mutant or small interfering RNA-mediat
242 of Src, PLD1, or PKCgamma via pharmacologic, dominant negative mutant, or siRNA approaches significan
244 ession of a Gbetagamma sequestrant, a GRK2/3 dominant-negative mutant, or siRNA-mediated knockdown in
245 periments using PTP1B(-/-) fibroblast lines, dominant-negative mutants, or small interfering RNAs ind
246 1 shRNA (DPSC/ORAI1sh) or overexpressed with dominant negative mutant ORAI1(E106Q) (DPSC/E106Q) exhib
247 sed on the effects of expression of either a dominant-negative mutant Orai3 that is an essential comp
250 en, California) gene switch technology and a dominant-negative mutant polypeptide of herpes simplex v
254 tively active Rab8, and coexpression of this dominant-negative mutant Rab8 blocks trafficking to the
256 versely, inhibition of STAT3 using siRNAs or dominant negative mutants reduced KIM-1 expression in a
257 levels of Cdc42-GTP, transfection of a Cdc42 dominant-negative mutant reduced cell growth and migrati
261 ls through RNA interference or expression of dominant-negative mutants results in differentiation.
262 olerance in HSFA6b-null, overexpression, and dominant negative mutants revealed that HSFA6b is a posi
263 phosphorylation and was reduced by the RhoA dominant negative mutant RhoA(T19N) and Rho and myosin l
264 smooth muscle contraction by expressing the dominant negative mutants RhoA T19N and cdc42 T17N, and
265 lls expressing either wild-type RNase L or a dominant-negative mutant RNase L were used to examine th
266 -mediated apoptotic cascade with a caspase-8 dominant-negative mutant significantly blocked sorafenib
267 ion by adenovirus-mediated expression of its dominant negative mutant, significantly attenuated 14,15
268 e inhibition of endogenous H-Ras by specific dominant-negative mutant/siRNA markedly ablated the HO-1
269 rsely regulated by NF2, through the use of a dominant-negative mutant, small hairpin RNA or a small m
270 orced expression of constitutively active or dominant-negative mutant STAT5A in mouse brain ECs, we f
272 on via adenovirus-mediated expression of its dominant-negative mutant suppressed 15(S)-HETE-induced H
273 r blocking their signaling by overexpressing dominant negative mutants suppresses netrin-1-induced gr
274 pseudosubstrate inhibitor, or its siRNA, or dominant negative mutants suppresses the cross-desensiti
276 and elevated thyroid hormone levels due to a dominant-negative mutant T(3) receptor (TRbeta(PV)) that
277 inactivation of Cdc42 by overexpressing its dominant-negative mutant T17N in Sertoli cell epithelium
278 tive form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcript
279 ling assay, we showed that the expression of dominant-negative mutant TAp73 expression plasmid (p73DD
282 2 mutations detected so far are recessive, a dominant negative mutant that affects GlyT2 trafficking
286 interfering RNA (siRNA) duplexes and ac-Cbl dominant negative mutant to show that c-Cbl is critical
287 pecific for Sdc1 and Sdc4 recognition act as dominant negative mutants to block cell spreading or cel
288 TEN lipid and protein phosphatase may act as dominant-negative mutants to suppress endogenous PTEN an
289 s TTP and BRF proteins, or overexpression of dominant-negative mutant TTP proteins, impairs the local
291 ession of UBE2L3 and LUBAC, but abolished by dominant-negative mutant UBE2L3 (C86S), or UBE2L3 silenc
293 gether with pharmacological agents, RNAi and dominant negative mutants, we have demonstrated that tar
294 acological inhibitors, RNA interference, and dominant-negative mutants, we define the mechanisms invo
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。